The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical Study
The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical Study
Not yet recruiting · NCT07724951 · Registry updated 2026-07-27Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical Study | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Not yet recruiting | Not stated | 2026-07-27 | NCT07724951 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Shanghai Zhongshan Hospital | 347 |
| Yunnan Cancer Hospital | 46 |
8 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Harbin Medical University Cancer Hospital | Harbin | China | 51 |
| Sun Yat-sen Memorial Hospital | Guangzhou | China | 16 |
| Sun Yat-Sen University Cancer Center | Guangzhou | China | 113 |
| The Affiliated Hospital of Qingdao University | Qingdao | China | 48 |
| The First Affiliated Hospital of Guangxi Medical University | Nanning | China | 33 |
| Yunnan Cancer Hospital | Kunming | China | 1 |
| Zhong Shan Hospital Fudan University | Shanghai | China | 2 |
| ZhuJiang Hospital of Southern Medical University | Guangzhou | China | 27 |